Friday, 29 June 2018 17:39

Anticoagulation news items. Week commencing 18th and 25th June 2018

Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States


Retrospective cohort study (n=2351 on apixaban; 23,172 on warfarin) found apixaban use may be linked to lower risk of major bleeding vs. warfarin (HR 0.72, 95% CI 0.59-0.87; P<0.001) with standard 5mg BD dose also linked to reductions in thromboembolic and mortality risk.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: